Form 4: Dyne Therapeutics Director Jason P. Rhodes Acquires Shares
SEC Form 4 Filing
Director Jason P. Rhodes reports acquisition of Dyne Therapeutics shares through indirect ownership.
Summary
- On January 27, 2025, Jason P. Rhodes, a director of Dyne Therapeutics, acquired 1,111,111 shares of common stock at a price of $13.50 per share.
- Following the transaction, Rhodes indirectly owns 1,958,427 shares through Atlas Venture Opportunity Fund II, L.P., 5,697,508 shares through Atlas Venture Fund XI, L.P., 15,962 shares through AVA XI LP, and 1,458,568 shares through Atlas Venture Opportunity Fund I, L.P.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing, indicating a neutral sentiment. It simply reports a transaction.
Industry Context
This filing is a routine disclosure of stock ownership changes by a company insider, which is common in the biotechnology industry.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects insider confidence, but the effect is likely minimal given the indirect nature of the ownership.
Key Dates
| Date | Description |
|---|---|
| 01/27/2025 | Date of transaction: Acquisition of common stock. |
| 01/29/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.